Kenya Seeks Vaccine Self-Reliance for Pandemic Preparedness

Kenya is prioritizing domestic vaccine production to enhance its preparedness for future health crises and reduce reliance on imported vaccines. The nation’s experience during the COVID-19 pandemic, where Africa faced delays in vaccine access, has spurred this initiative.

Vaccine Manufacturing Initiative

Kenya aims to produce 60–70% of its vaccine supply locally, establishing the Kenya Biobank Institute to facilitate this goal. The government views this as a critical step toward health security, economic growth, industrial development, and national sovereignty. The shift is also driven by the anticipated phasing out of support from the Global Alliance for Vaccines and Immunization (GAVI) by 2030.

Strengthening the Health System

Alongside vaccine production, Kenya is bolstering its overall health system through science, innovation, and local manufacturing. KEMRI has been designated a strategic national institution, and a State Department for Science, Research, and Innovation has been established. A 10-year Science, Research, and Innovation Master Plan (2026–2036) is in place, with research funding projected to increase from 0.8% to 2% of GDP.

Universal Health Coverage and Digitalization

Universal Health Coverage (UHC) is a central focus of Kenya’s health agenda, supported by sustainable financing, a skilled health workforce, community-based systems, and a strong digital health ecosystem. Digitization efforts include a real-time bed access rule system that tracks hospital bed occupancy across public, private, and faith-based facilities. This system improves efficiency, reduces overcrowding, and enhances billing accuracy.

KEMRI Annual Conference

The 16th Kenya Medical Research Institute (KEMRI) Annual Scientific and Research Conference (KASH) convened scientists, policymakers, industry leaders, and development partners. The conference theme was “The Future of Health: Scientific Research, Innovation, Technologies and Manufacturing for a Resilient Universal Health Coverage.” Dr. Cecilia Mbae, Chair of KASH, commended Kenya’s progress in vaccine manufacturing and related areas, emphasizing the importance of translating research and policy into sustainable manufacturing capacity.